A variety of novel target drugs have been developed, such as ortho-pentameric protein-2, anti-connective tissue growth factor antibody, mesenchymal stem cells, etc., but basically all of them are in the laboratory or clinical trial stage.
1. Recombinant ortho-pentameric protein-2 human analog (PRM-151) has been shown to improve pulmonary fibrosis in animal models of fibrosis.
2. Anti-connective tissue growth factor antibody, Panrelumab, is a fully human recombinant monoclonal antibody, which has been found to slow the decline in lung function in patients with pulmonary fibrosis in phase II clinical studies.
3. mesenchymal stem cells (MSCs); however, to date, the results of all studies on MSCs for the treatment of pulmonary fibrosis have been inconclusive. Currently, there are several registered clinical studies conducted on stem cells for the treatment of pulmonary fibrosis.
All of the above drugs are new drugs for the treatment of pulmonary fibrosis, and some of them are in phase I-III clinical trials. It is not recommended for patients to buy and take them by themselves, and it is recommended to use them under the guidance of professional doctors.